Concept Life Sciences providing ‘fully integrated offering’ in the early development space

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/Rawpixel)
(Image: Getty/Rawpixel)

Related tags: API, Concept Life Sciences, Preclinical services, analytical

The drug discovery, development, and analytical service provider has opened a new facility in Sandwich, UK to support the development and manufacturing of APIs – a market expected to top $270bn by 2026.

The new clinical and niche commercial facility will add current good manufacturing practice (cGMP) active pharmaceutical ingredient (API) synthesis from gram-scale to multi-kilo capability, said Dr. Paul Doyle, chief scientific officer.

The facility and offering complements the company’s other sites, which provide analytical, stability, material science, and formulation services.

“Ultimately this results in a fully integrated offering in the early development space to support pharmaceutical and biotechnology companies throughout the development and manufacture of active pharmaceutical ingredients,”​ Doyle told us.

The company’s business has been driven by customer demand in what Doyle described as a growing marketplace – some forecasts suggest the API market will be worth more than $274.9bn by 2026, he said.

“Concept Life Sciences is seeing the highest demand from our customers when they are transitioning from late lead optimization through to preclinical and clinical development,”​ Doyle added.

“Adding cGMP API capabilities allows a seamless transition from gram-scale chemistry through to non-GMP and GMP production,”​ he said, “thus allowing us to support customers moving into these different phases of development.”

Related news

Show more

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Standardizing data with NCI controlled terminology

Standardizing data with NCI controlled terminology

Formedix | 18-Jul-2022 | Technical / White Paper

The use of consistent terminology within and between studies is critical to enabling an efficient trial process. CDISC standards such as CDASH, SDTM, SEND...

Planning Your First-In-Human Trial

Planning Your First-In-Human Trial

Altasciences | 15-Jul-2022 | Technical / White Paper

A first-in-human (FIH) clinical trial is a significant milestone in the development of a potential new drug. A successfully conducted FIH trial provides...

Related suppliers

Follow us

Products

View more

Webinars